Antileukemic and long-term effects of two regimens with or without TBI in allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia

Bone Marrow Transplantation

Volumn 34, Issue 8, 2004, Pages 667-673

  Dai, Q Y ^a   Souillet, G ^b   Bertrand, Y ^b   Galambrun, C ^b   Bleyzac, N ^b   Manel, A M ^b   Bruno, B ^b   Souillet, A L ^b   Homole, E ^b   Pages, M P ^b   Berlier, P ^b   David, M ^b   Berthier, J C ^b   Massenavette, B ^b   Contamin, B ^b   Philippe, N ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b HÔPITAL DEBROUSSE   (France)

Author keywords

ALL; Allogeneic BMT; BMT conditioning; Children; Late effect

Indexed keywords

ANDROGEN; ANTILEUKEMIC AGENT; BUSULFAN; CYCLOSPORIN; CYTARABINE; GLUCOCORTICOID; MELPHALAN; METHOTREXATE; RECOMBINANT GROWTH HORMONE; THYMOCYTE ANTIBODY; THYROID HORMONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; CANCER RECURRENCE; CANCER RISK; CATARACT; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; DELAYED PUBERTY; DONOR; DRUG DOSE REGIMEN; DRUG MEGADOSE; EXOSTOSIS; FEMALE; FEMUR HEAD NECROSIS; GRAFT VERSUS HOST REACTION; GROWTH HORMONE DEFICIENCY; HIGH RISK PATIENT; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; LONG TERM CARE; MALE; METABOLIC DISORDER; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; SIBLING; THROMBOTIC THROMBOCYTOPENIC PURPURA; THYROID CARCINOMA; TOOTH DISEASE; VEIN OCCLUSION; WHOLE BODY RADIATION;

ADOLESCENT; BONE MARROW TRANSPLANTATION; BUSULFAN; CHILD; CHILD, PRESCHOOL; CYTARABINE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOPHENOTYPING; KARYOTYPING; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MELPHALAN; PHOSPHORIC ACID ESTERS; RECURRENCE; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 6444232248     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704605     Document Type: Article

References (32)

1. Kersey JH. Fifty years of studies of the biology and therapy of childhood leukemia. Blood 1997; 90: 4243-4251.
2. Pinkel D. Treatment of acute lymphoblastic leukemia in a second remission. New Engl J Med 1995; 332: 823-826.
3. Dini G, Cornish JM, Gadner H et al. Bone marrow transplant indications for childhood leukemia: achieving a consensus. Bone Marrow Transplant 1996; 18: 4-7.
4. Brochstein JA, Kernan NA, Groshen S et al. Allogeneic bone marrow transplantation after hyperfractionated total body irradiation and cyclophosphamide in children with acute leukemiac. New Engl J Med 1987; 317: 1618-1624.
5. Blume KG, Forman SJ, O'Donnel MR et al. Total body irradiation and high-dose etoposide: a new preparative regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 1987; 69: 1015-1020.
6. Coccia PF, Strandjord SE, Warkentin PI et al. High dose cytosine arabinoside and fractioned total-body irradiation: an improved preparative regimen for bone marrow transplantation of children with acute lymphoblastic leukemia in remission. Blood 1988; 71: 888-893.
7. Bordigoni P, Esperou H, Souillet G et al. Total body irradiation, high dose cytosine arabinoside and melphalan followed by allogeneic bone marrow transplantation from HLA-identical siblings in the treatment of children with acute lymphoblastic leukemia after relapse while receiving chemotherapy: a Societe Francaise de Greffe de Moelle study. Br J Haematol 1998; 102: 656-665.
8. Sanders JE, Pritchard S, Mahoney P et al. Growth and development following marrow transplantation for leukemia. Blood 1986; 68: 1129-1135.
9. Sanders JE, Bucker CD, Leonard JM et al. Late effects on gonadal function of cyclophosphamide, total body irradiation, and marrow transplantation. Transplantation 1983; 36: 252-255.
10. Sklar CA, Kim TH, Ramsay NKC et al. Thyroid dysfunction among long-term survivors of bone marrow transplantation. Am J Med 1982; 73: 688-694.
11. Von Bueltzingsloewen A, Esperou-Bourdeau H, Souillet G et al. Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a cooperative study of the Societé Francaise de Greffe de Moelle. Bone Marrow Transplant 1995; 16: 521-527.
12. Matsuyama T Kojima S, Kato K. Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen. Bone Marrow Transplant 1998; 22: 21-26.
13. Vilmer E, Suciu S, Ferster A et al. Long term results of three randomized trials (58831,58832,58881) in childhood acute lymphocytic leukemia: a CLCG-EORTC report. Leukemia 2000; 14: 2257-2266.
14. Bordigoni P, Vernant JP, Souillet G et al. Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia in first remission: a cooperative study of the group d'Etude de la Greffe de Moelle Osseuse. J Clin Oncol 1989; 7: 747-753.
15. Saarinen UM, Mellander L, Nyson K et al. Allogeneic bone marrow transplantation in first remission for children with very high risk acute lymphoblastic leukemia: a retrospective case control-study in Nordic countries (NOPHO). Bone Marrow Transplant 1996; 17: 357-363.
16. Uderzo C, Valsecchi MG, Balduzzi A et al. Allogeneic bone marrow transplantation versus chemotherapy in high risk childhood acute lymphoblastic leukemia in first remission. Br J Haematol 1997; 96: 387-394.
17. Wheeler KA, Richards SM, Bailley CC et al. Bone marrow transplantation versus chemotherapy in the treatment of very high risk childhood acute lymphoblastic leukemia in first remission: result from Medical Research Council UKALL X an XI. Blood 2000; 96: 2412-2418.
18. Sadowitz PD, Smith SD, Shuster J et al. Treatment of late bone marrow relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 1993; 81: 602-609.
19. Boulad F, Steinherz P, Reyes B et al. Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single-institution Study. J Clin Oncol 1999; 17: 197-207.
20. Gordon BG, Warkentin PI, Strandjord SE et al. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation. Bone Marrow Transplant 1997; 20: 5-10.
21. Ringdén O, Ruutu T, Remberger M et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723-2730.
22. Ringdén O, Labopin M, Tura S et al. A comparison of busulfan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukemia. Br J Haematol 1996; 93: 637-645.
23. Davies SM, Ramsay NCK, Klein JP et al. Comparison of preparative regimens, in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 2000; 18: 340-347.
24. Mineishi S, Longo WL, Atkinson ME et al. Addition of high-dose Ara C to the BMT conditioning regimen reduces leukemia relapse without an increase in toxicity. Bone Marrow Transplant 1999; 23 1217-1222.
25. Sklar C. Growth and endocrine disturbance after bone marrow transplantation in childhood. Acta Paediatr Suppl 1995; 411: 57-61.
26. Witherspoon RP, Fisher LD, Schoch G et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. New Engl J Med 1989; 321: 784-789.
27. Shalet SM, Didi M, Ogilvy-Stuart et al. Growth and endocrine function after bone marrow transplantation. Clin Endocrinol 1995; 42: 333-339.
28. Wingard JR, Piotnick LP, Freemer CS et al. Growth in children after bone marrow transplantation: busulfan plus cyclophosphamide versus cyclophosphamide plus total body irradiation. Blood 1992; 79: 1068-1073.
29. Michel G, Solié G, Gebhard F et al. Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first remission: the impact of conditioning regimen without total body irradiation. A report from the Socié té Française de Greffe de Moelle. J Clin Oncol 1997; 15: 2238-2246.
30. Dahllöf G, Barr M, Bolme P et al. Disturbance in tental development after total body irradiation in bone marrow transplant recipients. Oral Surg Oral Med Oral Pathol 1988; 65: 4144.
31. Bruno B, Souillet G, Bertrand Y et al. Effects of allogeneic bone marrow transplantation on pulmonary function in 80 children in a single paediatric centre. Bone Marrow Transplant 2004; 7: 1043-1057.
32. Bleyzac N, Souillet G, Magron P et al. Improved clinical outcome of pediatric bone marrow recipients by using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone marrow transplantation. 2001; 28: 743-751.